Bevacizumab, a recombinant humanised monoclonal antibody against vascular endothelial growth factor (VEGF), has been reported to improve progression-free survival (PFS) in patients with gynaecological cancers [8,14,15] and overall survival (OS) in high-risk EOC populations [14,15] as well as patients with cervical cancer [16]. Here, VEGFA is linked to cervical carcinoma.